

# Filipe B. Rodrigues

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5061323/filipe-b-rodrigues-publications-by-year.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

74  
papers

1,344  
citations

19  
h-index

35  
g-index

94  
ext. papers

1,821  
ext. citations

5.3  
avg, IF

4.98  
L-index

#	Paper	IF	Citations
74	Safety and Feasibility of Research Lumbar Puncture in Huntington's Disease: The HDClarity Cohort and Bioresource.. <i>Journal of Huntingtons Disease</i> , <b>2022</b> , 11, 59-69	1.9	1
73	A MDS Evidence-Based Review on Treatments for Huntington's Disease. <i>Movement Disorders</i> , <b>2021</b> ,	7	4
72	Botulinum toxin type A versus anticholinergics for cervical dystonia. <i>The Cochrane Library</i> , <b>2021</b> , 4, CD004312	3.12	0
71	Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington's disease. <i>Journal of Neurochemistry</i> , <b>2021</b> , 158, 539-553	6	5
70	The use of wearable/portable digital sensors in Huntington's disease: A systematic review. <i>Parkinsonism and Related Disorders</i> , <b>2021</b> , 83, 93-104	3.6	8
69	Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington's disease. <i>Scientific Reports</i> , <b>2021</b> , 11, 3481	4.9	3
68	Growth and renal function dynamics of renal oncocytomas in patients on active surveillance. <i>BJU International</i> , <b>2021</b> , 128, 722-727	5.6	4
67	Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis. <i>Lancet Neurology</i> , <b>2020</b> , 19, 502-512	24.1	56
66	Strategies to minimize placebo effects in research investigations. <i>International Review of Neurobiology</i> , <b>2020</b> , 153, 49-70	4.4	2
65	Huntington's Disease Clinical Trials Corner: April 2020. <i>Journal of Huntingtons Disease</i> , <b>2020</b> , 9, 185-197	1.9	24
64	Characterizing White Matter in Huntington's Disease. <i>Movement Disorders Clinical Practice</i> , <b>2020</b> , 7, 52-60	2	6
63	Prognostic value of phrenic nerve conduction study in amyotrophic lateral sclerosis: Systematic review and meta-analysis. <i>Clinical Neurophysiology</i> , <b>2020</b> , 131, 106-113	4.3	2
62	Botulinum toxin type A therapy for hemifacial spasm. <i>The Cochrane Library</i> , <b>2020</b> , 11, CD004899	5.2	4
61	Botulinum toxin type A therapy for blepharospasm. <i>The Cochrane Library</i> , <b>2020</b> , 11, CD004900	5.2	5
60	Botulinum toxin type A therapy for cervical dystonia. <i>The Cochrane Library</i> , <b>2020</b> , 11, CD003633	5.2	7
59	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease. <i>PLoS ONE</i> , <b>2020</b> , 15, e0233820	3.7	3
58	Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington's disease. <i>Science Translational Medicine</i> , <b>2020</b> , 12,	17.5	24

57	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease <b>2020</b> , 15, e0233820		
56	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease <b>2020</b> , 15, e0233820		
55	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease <b>2020</b> , 15, e0233820		
54	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease <b>2020</b> , 15, e0233820		
53	Cerebrospinal fluid flow dynamics in Huntington's disease evaluated by phase contrast MRI. <i>European Journal of Neuroscience</i> , <b>2019</b> , 49, 1632-1639	3.5	1
52	Anti-TNF Drugs for Chronic Uveitis in Adults-A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Medicine</i> , <b>2019</b> , 6, 104	4.9	15
51	Morphine in acute coronary syndrome: systematic review and meta-analysis. <i>BMJ Open</i> , <b>2019</b> , 9, e025233		12
50	Comparison of the Huntington's Disease like 2 and Huntington's Disease Clinical Phenotypes. <i>Movement Disorders Clinical Practice</i> , <b>2019</b> , 6, 302-311	2.2	9
49	Huntington's Disease Clinical Trials Corner: January 2019. <i>Journal of Huntingtons Disease</i> , <b>2019</b> , 8, 115-125		19
48	Huntington's Disease Clinical Trials Corner: June 2019. <i>Journal of Huntingtons Disease</i> , <b>2019</b> , 8, 363-371	1.9	18
47	Deep brain stimulation for dystonia. <i>The Cochrane Library</i> , <b>2019</b> , 1, CD012405	5.2	23
46	Rating Scales and Performance-based Measures for Assessment of Functional Ability in Huntington's Disease: Critique and Recommendations. <i>Movement Disorders Clinical Practice</i> , <b>2018</b> , 5, 361-372	2.2	12
45	Efficacy and safety of intravitreal anti-tumour necrosis factor drugs in adults with non-infectious uveitis - a systematic review. <i>Acta Ophthalmologica</i> , <b>2018</b> , 96, e665-e675	3.7	13
44	Quality of Life in Huntington's Disease: Critique and Recommendations for Measures Assessing Patient Health-Related Quality of Life and Caregiver Quality of Life. <i>Movement Disorders</i> , <b>2018</b> , 33, 742-749		12
43	Huntington's Disease Clinical Trials Corner: February 2018. <i>Journal of Huntingtons Disease</i> , <b>2018</b> , 7, 89-98	1.9	36
42	Neurofilament light protein in blood predicts regional atrophy in Huntington disease. <i>Neurology</i> , <b>2018</b> , 90, e717-e723	6.5	42
41	Cerebrospinal fluid neurogranin and TREM2 in Huntington's disease. <i>Scientific Reports</i> , <b>2018</b> , 8, 4260	4.9	17
40	Huntington's Disease Clinical Trials Corner: August 2018. <i>Journal of Huntingtons Disease</i> , <b>2018</b> , 7, 279-286		17

39	Adverse events with botulinum toxin treatment in cervical dystonia: How much should we blame placebo?. <i>Parkinsonism and Related Disorders</i> , <b>2018</b> , 56, 16-19	3.6	8
38	Physician perception versus true efficacy of tetrabenazine for Huntington's disease. <i>Current Medical Research and Opinion</i> , <b>2018</b> , 34, 1537-1538	2.5	
37	Cardiac Harms of Sofosbuvir: Systematic Review and Meta-Analysis. <i>Drug Safety</i> , <b>2018</b> , 41, 77-86	5.1	13
36	Management of Small Renal Masses. <i>Radiology</i> , <b>2018</b> , 289, 272-273	20.5	1
35	Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease. <i>Science Translational Medicine</i> , <b>2018</b> , 10,	17.5	67
34	Perinatal insults and neurodevelopmental disorders may impact Huntington's disease age of diagnosis. <i>Parkinsonism and Related Disorders</i> , <b>2018</b> , 55, 55-60	3.6	1
33	Biofluid Biomarkers in Huntington's Disease. <i>Methods in Molecular Biology</i> , <b>2018</b> , 1780, 329-396	1.4	13
32	Tetrabenazine Versus Deutetrabenazine for Huntington's Disease: Twins or Distant Cousins?. <i>Movement Disorders Clinical Practice</i> , <b>2017</b> , 4, 582-585	2.2	31
31	Opicapone for the treatment of Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , <b>2017</b> , 18, 445-453	4.5	11
30	Placebo and nocebo responses in restless legs syndrome: A systematic review and meta-analysis. <i>Neurology</i> , <b>2017</b> , 88, 2216-2224	6.5	35
29	Survival, Mortality, Causes and Places of Death in a European Huntington's Disease Prospective Cohort. <i>Movement Disorders Clinical Practice</i> , <b>2017</b> , 4, 737-742	2.2	38
28	Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis. <i>Lancet Neurology</i> , <b>2017</b> , 16, 601-609	24.1	172
27	Thromboprophylaxis With Apixaban in Patients Undergoing Major Orthopedic Surgery: Meta-Analysis and Trial-Sequential Analysis. <i>Clinical Medicine Insights Blood Disorders</i> , <b>2017</b> , 10, 1179545X17704660	2.7	5
26	Overall Survival and Causes of Death in Neurodegeneration-An Overlooked and Underreported Theme. <i>JAMA Neurology</i> , <b>2017</b> , 74, 1379	17.2	1
25	Meta-research metrics matter: letter regarding article "indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease". <i>Journal of Clinical Movement Disorders</i> , <b>2017</b> , 4, 19	2.8	8
24	Intracerebral hemorrhage as a manifestation of cerebral hyperperfusion syndrome after carotid revascularization: systematic review and meta-analysis. <i>Acta Neurochirurgica</i> , <b>2017</b> , 159, 2089-2097	3	13
23	Frequency of post-stroke electroencephalographic epileptiform activity - a systematic review and meta-analysis of observational studies. <i>European Stroke Journal</i> , <b>2017</b> , 2, 361-368	5.6	2
22	Fifteen Years of Clinical Trials in Huntington's Disease: A Very Low Clinical Drug Development Success Rate. <i>Journal of Huntingtons Disease</i> , <b>2017</b> , 6, 157-163	1.9	39

21	PO104 Placebo and nocebo responses in rls: a meta-analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2017</b> , 88, A39.1-A39	5.5	
20	Botulinum toxin type A therapy for cervical dystonia. <i>The Cochrane Library</i> , <b>2017</b> , 12, CD003633	5.2	34
19	Clinical Trials Corner: September 2017. <i>Journal of Huntingtons Disease</i> , <b>2017</b> , 6, 255-263	1.9	28
18	Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease. <i>Journal of Neurochemistry</i> , <b>2016</b> , 139, 22-5	6	37
17	Anterior ischemic optic neuropathy and hematologic malignancy: a systematic review of case reports and case series. <i>Canadian Journal of Ophthalmology</i> , <b>2016</b> , 51, 459-466	1.4	
16	Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. <i>The Cochrane Library</i> , <b>2016</b> , 10, CD004314	5.2	19
15	D4 Prediction of huntington's disease phenotype by cerebrospinal fluid biomarkers of inflammation and cell death. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2016</b> , 87, A35.1-A35	5.5	
14	Endovascular treatment versus medical care alone for ischaemic stroke: systematic review and meta-analysis. <i>BMJ, The</i> , <b>2016</b> , 353, i1754	5.9	120
13	Deep brain stimulation for dystonia. <i>The Cochrane Library</i> , <b>2016</b> ,	5.2	78
12	Extended daily dialysis versus intermittent hemodialysis for acute kidney injury: A systematic review. <i>Journal of Critical Care</i> , <b>2016</b> , 33, 271-3	4	5
11	Autosomal dominant polycystic kidney disease and coronary artery dissection or aneurysm: a systematic review. <i>Renal Failure</i> , <b>2016</b> , 38, 493-502	2.9	8
10	Her Aching Bones: Atypical Parathyroid Adenoma. <i>American Journal of Medicine</i> , <b>2016</b> , 129, 260-2	2.4	1
9	Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington's Disease. <i>PLoS ONE</i> , <b>2016</b> , 11, e0163479	3.7	35
8	K4 The cost and value of a huntington's disease multidisciplinary team meeting. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2016</b> , 87, A80.2-A80	5.5	
7	Botulinum toxin type B for cervical dystonia. <i>The Cochrane Library</i> , <b>2016</b> , CD004315	5.2	19
6	Bilateral gigantic earlobe keloids. <i>Clinical Medicine</i> , <b>2016</b> , 16, 91	1.9	
5	Psychogenic non-epileptic seizures in early Huntington's disease. <i>Practical Neurology</i> , <b>2016</b> , 16, 452-454	2.4	2
4	Mechanical Thrombectomy and Functional Outcomes After Stroke. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 315, 1791-2	27.4	1

3	Caffeine and Neuroprotection in Parkinson's Disease. <i>Current Topics in Neurotoxicity</i> , <b>2015</b> , 233-272		1
2	Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis. <i>Heart</i> , <b>2015</b> , 101, 1204-11	5.1	87
1	Longitudinal dynamics of mutant huntingtin and neurofilament light in Huntington's disease: the prospective HD-CSF study		2